135 related articles for article (PubMed ID: 32744980)
1. Epigenetic Evaluation of N-(2-hydroxyphenyl)-2-Propylpentanamide, a Valproic Acid Aryl Derivative with Activity Against HeLa Cells.
Luna-Palencia GR; Correa-Basurto J; Trujillo-Ferrara J; Meraz-Ríos MA; Vásquez- Moctezuma I
Curr Mol Pharmacol; 2021 Oct; 14(4):570-578. PubMed ID: 32744980
[TBL] [Abstract][Full Text] [Related]
2. N-(2-hydroxyphenyl)-2-propylpentanamide, a valproic acid aryl derivative designed in silico with improved anti-proliferative activity in HeLa, rhabdomyosarcoma and breast cancer cells.
Prestegui-Martel B; Bermúdez-Lugo JA; Chávez-Blanco A; Dueñas-González A; García-Sánchez JR; Pérez-González OA; Padilla-Martínez II; Fragoso-Vázquez MJ; Mendieta-Wejebe JE; Correa-Basurto AM; Méndez-Luna D; Trujillo-Ferrara J; Correa-Basurto J
J Enzyme Inhib Med Chem; 2016; 31(sup3):140-149. PubMed ID: 27483122
[TBL] [Abstract][Full Text] [Related]
3. Docking Studies of Glutamine Valproic Acid Derivative (S)-5- amino-2-(heptan-4-ylamino)-5-oxopentanoic Acid (Gln-VPA) on HDAC8 with Biological Evaluation in HeLa Cells.
Martínez-Ramos F; Luna-Palencia GR; Vásquez-Moctezuma I; Méndez-Luna D; Fragoso-Vázquez MJ; Trujillo-Ferrara J; Meraz-Ríos MA; Mendieta-Wejebe JE; Correa-Basurto J
Anticancer Agents Med Chem; 2016; 16(11):1485-1490. PubMed ID: 26845132
[TBL] [Abstract][Full Text] [Related]
4.
Contis-Montes de Oca A; Rodarte-Valle E; Rosales-Hernández MC; Abarca-Rojano E; Rojas-Hernández S; Fragoso-Vázquez MJ; Mendieta-Wejebe JE; Correa-Basurto AM; Vázquez-Moctezuma I; Correa-Basurto J
Oncotarget; 2018 Sep; 9(70):33368-33381. PubMed ID: 30279967
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the anticancer properties of a novel valproic acid prodrug to leading histone deacetylase inhibitors.
Tarasenko N; Chekroun-Setti H; Nudelman A; Rephaeli A
J Cell Biochem; 2018 Apr; 119(4):3417-3428. PubMed ID: 29135083
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells.
Dejligbjerg M; Grauslund M; Litman T; Collins L; Qian X; Jeffers M; Lichenstein H; Jensen PB; Sehested M
Mol Cancer; 2008 Sep; 7():70. PubMed ID: 18789133
[TBL] [Abstract][Full Text] [Related]
7. Teratogenic effects mediated by inhibition of histone deacetylases: evidence from quantitative structure activity relationships of 20 valproic acid derivatives.
Eikel D; Lampen A; Nau H
Chem Res Toxicol; 2006 Feb; 19(2):272-8. PubMed ID: 16485903
[TBL] [Abstract][Full Text] [Related]
8. Docking and QSAR Studies of Aryl-valproic Acid Derivatives to Identify Antiproliferative Agents Targeting the HDAC8.
Martínez-Pacheco H; Ramírez-Galicia G; Vergara-Arias M; Gertsch J; Fragoso-Vazquez JM; Mendez-Luna D; Abujamra AL; Cristina CL; Cecilia RM; Mendoza-Lujambio I; Correa-Basurto J
Anticancer Agents Med Chem; 2017; 17(7):927-940. PubMed ID: 27774878
[TBL] [Abstract][Full Text] [Related]
9. Valproic acid, but not levetiracetam, selectively decreases HDAC7 and HDAC2 expression in human ovarian cancer cells.
Kwiecińska P; Wróbel A; Taubøll E; Gregoraszczuk EŁ
Toxicol Lett; 2014 Jan; 224(2):225-32. PubMed ID: 24200999
[TBL] [Abstract][Full Text] [Related]
10. Anti-epileptic activity, toxicity and teratogenicity in CD1 mice of a novel valproic acid arylamide derivative, N-(2-hydroxyphenyl)-2-propylpentanamide.
Cristóbal-Luna JM; Correa-Basurto J; Mendoza-Figueroa HL; Chamorro-Cevallos G
Toxicol Appl Pharmacol; 2020 Jul; 399():115033. PubMed ID: 32387339
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of TrkB Expression and Signaling by Valproic Acid and Other Histone Deacetylase Inhibitors.
Dedoni S; Marras L; Olianas MC; Ingianni A; Onali P
J Pharmacol Exp Ther; 2019 Sep; 370(3):490-503. PubMed ID: 31308194
[TBL] [Abstract][Full Text] [Related]
12. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
13. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
Liu S; Klisovic RB; Vukosavljevic T; Yu J; Paschka P; Huynh L; Pang J; Neviani P; Liu Z; Blum W; Chan KK; Perrotti D; Marcucci G
J Pharmacol Exp Ther; 2007 Jun; 321(3):953-60. PubMed ID: 17389244
[TBL] [Abstract][Full Text] [Related]
14. Effect of Valproic Acid on the Class I Histone Deacetylase 1, 2 and 3, Tumor Suppressor Genes p21WAF1/CIP1 and p53, and Intrinsic Mitochondrial Apoptotic Pathway, Pro- (Bax, Bak, and Bim) and anti- (Bcl-2, Bcl-xL, and Mcl-1) Apoptotic Genes Expression, Cell Viability, and Apoptosis Induction in Hepatocellular Carcinoma HepG2 Cell Line.
Sanaei M; Kavoosi F
Asian Pac J Cancer Prev; 2021 Feb; 22(S1):89-95. PubMed ID: 33576217
[TBL] [Abstract][Full Text] [Related]
15. HDAC inhibition delays cell cycle progression of human bladder cancer cells in vitro.
Vallo S; Xi W; Hudak L; Juengel E; Tsaur I; Wiesner C; Haferkamp A; Blaheta RA
Anticancer Drugs; 2011 Nov; 22(10):1002-9. PubMed ID: 21822119
[TBL] [Abstract][Full Text] [Related]
16. Three amino acid derivatives of valproic acid: design, synthesis, theoretical and experimental evaluation as anticancer agents.
Luna-Palencia GR; Martinez-Ramos F; Vasquez-Moctezuma I; Fragoso-Vazquez MJ; Mendieta-Wejebe JE; Padilla-Martínez II; Sixto-Lopez Y; Mendez-Luna D; Trujillo-Ferrara J; Meraz-Rios MA; Fonseca-Sabater Y; Correa-Basurto J
Anticancer Agents Med Chem; 2014; 14(7):984-93. PubMed ID: 24476311
[TBL] [Abstract][Full Text] [Related]
17. Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo.
Shabbeer S; Kortenhorst MS; Kachhap S; Galloway N; Rodriguez R; Carducci MA
Prostate; 2007 Jul; 67(10):1099-110. PubMed ID: 17477369
[TBL] [Abstract][Full Text] [Related]
18. The G1 phase arrest and apoptosis by intrinsic pathway induced by valproic acid inhibit proliferation of BGC-823 gastric carcinoma cells.
Zhao X; Yang W; Shi C; Ma W; Liu J; Wang Y; Jiang G
Tumour Biol; 2011 Apr; 32(2):335-46. PubMed ID: 21113745
[TBL] [Abstract][Full Text] [Related]
19. Exploring the biotransformation of N-(2-hydroxyphenyl)-2-propylpentanamide (an aryl valproic acid derivative) by CYP2C11, using in silico predictions and in vitro studies.
Mendieta-Wejebe JE; Silva-Trujillo A; Bello M; Mendoza-Figueroa HL; Galindo-Alvarez NL; Albores A; Tamay-Cach F; Rosales-Hernández MC; Romero-Castro A; Correa-Basurto J
J Pharm Pharmacol; 2020 Jul; 72(7):938-955. PubMed ID: 32307724
[TBL] [Abstract][Full Text] [Related]
20. Cellular Effects of the Antiepileptic Drug Valproic Acid in Glioblastoma.
Eckert M; Klumpp L; Huber SM
Cell Physiol Biochem; 2017; 44(4):1591-1605. PubMed ID: 29212069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
